Barclays PLC Boosts Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Barclays PLC lifted its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 362.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 170,546 shares of the medical technology company's stock after buying an additional 133,653 shares during the quarter. Barclays PLC owned approximately 0.12% of Alphatec worth $948,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers increased its position in Alphatec by 2.6% during the second quarter. Rhumbline Advisers now owns 143,474 shares of the medical technology company's stock worth $1,499,000 after buying an additional 3,676 shares in the last quarter. Envestnet Asset Management Inc. increased its position in Alphatec by 5.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 404,866 shares of the medical technology company's stock worth $4,231,000 after purchasing an additional 22,047 shares in the last quarter. Hsbc Holdings PLC raised its stake in Alphatec by 130.1% in the 2nd quarter. Hsbc Holdings PLC now owns 33,403 shares of the medical technology company's stock valued at $347,000 after purchasing an additional 18,888 shares during the last quarter. First Eagle Investment Management LLC purchased a new position in Alphatec in the 2nd quarter valued at about $1,071,000. Finally, Granite Investment Partners LLC boosted its stake in shares of Alphatec by 130.2% during the 2nd quarter. Granite Investment Partners LLC now owns 664,201 shares of the medical technology company's stock worth $6,941,000 after purchasing an additional 375,621 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Alphatec

In other news, EVP David Sponsel sold 58,283 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the sale, the executive vice president now owns 502,311 shares of the company's stock, valued at $5,379,750.81. This represents a 10.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Barclays boosted their price objective on shares of Alphatec from $19.00 to $20.00 and gave the company an "overweight" rating in a research report on Tuesday, November 19th. Needham & Company LLC increased their price target on Alphatec from $13.00 to $16.00 and gave the stock a "buy" rating in a research note on Monday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research report on Tuesday. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Alphatec presently has an average rating of "Moderate Buy" and a consensus price target of $17.44.

Alphatec Trading Up 2.1 %

Shares of Alphatec stock traded up $0.23 during trading hours on Wednesday, reaching $11.35. The stock had a trading volume of 2,025,219 shares, compared to its average volume of 2,012,119. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -8.87 and a beta of 1.41. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $17.34. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The firm has a 50 day simple moving average of $9.54 and a two-hundred day simple moving average of $8.00.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.